We’ve been accepted into Caelestinus, a global healthtech incubator focused on FHIR interoperability and digital health data standards. Over the next three months (March-June 2026), we’ll be working with InterSystems, IKEM (Europe’s largest transplant center), and leading healthcare technology experts to integrate VIOSync into the interoperability infrastructure that enables clinical AI systems to actually deploy in hospital environments.

The Interoperability Problem Clinical AI Can’t Ignore

Clinical AI that works in demos often fails in real hospitals, not because the models are wrong, but because the data infrastructure doesn’t exist to support them.

VIOSync needs real-time access to vital signs, lab results, and clinical context to predict sepsis risk up to 48 hours in advance. That data lives in dozens of different systems:

• Electronic Health Records (EHRs) – Epic, Oracle Health, InterSystems, Allscripts, and dozens of regional systems

• Patient monitoring devices – Philips, GE Healthcare, Dräger, each with proprietary data formats

• Laboratory information systems (LIS) – running on separate infrastructure with inconsistent data models

• Radiology PACS, pharmacy systems, ICU flowsheets – all using different standards

Most of these systems don’t talk to each other easily. FHIR (Fast Healthcare Interoperability Resources) is the emerging standard designed to solve this, but implementation is complex, fragmented, and varies wildly across hospitals.

This is the gap between “our AI works” and “our AI deploys”. Caelestinus exists to help companies bridge it.

About Caelestinus

Caelestinus is a 100% virtual, 3-month incubator focused exclusively on digital health interoperability. Named after a historical healthtech pioneer who ushered in modern surgery, the program is designed to turn healthcare innovations into deployable, interoperable solutions.

The program is powered by InterSystems, the company behind healthcare data infrastructure used by many of the world’s largest hospital systems, and supported by:

• IKEM (Institute for Clinical and Experimental Medicine) – Europe’s largest transplant center, providing access to real-world clinical validation

• AWS – cloud infrastructure and healthcare data solutions

• Novartis – pharmaceutical and healthcare innovation perspective

• INBUI.COM – healthcare technology ecosystem connections

Caelestinus takes no equity, charges no fees, and requires only time commitment from participating companies. The focus is purely on helping healthcare innovations become interoperable and deployable.

Why This Matters for VIOSync

VIOSync is designed to detect sepsis risk up to 48 hours in advance through multimodal data fusion, combining vital signs, lab results, and clinical context. That requires pulling real-time data from multiple hospital systems that weren’t built to communicate with each other.

Caelestinus gives us three critical capabilities:

1. FHIR Implementation Expertise

FHIR is the standard, but implementation varies significantly across hospital systems. InterSystems mentors bring hands-on experience from deploying healthcare data platforms in real hospital environments, understanding not just the technical specs, but the deployment realities.

For VIOSync, this means learning how to integrate with EHR systems, patient monitoring devices, and lab information systems using FHIR standards that actually work in production, not just in documentation.

2. Clinical Validation Infrastructure

Through IKEM (Europe’s largest transplant center) and Caelestinus’s healthcare network, we gain access to clinical validation pathways, testing VIOSync with real healthcare providers and getting feedback on workflow integration, alert fatigue, and clinical usability.

This is the gap between retrospective validation studies (which we’ve completed) and prospective clinical trials (which we’re preparing for). Caelestinus provides structured access to healthcare organizations willing to pilot interoperable health technologies.

3. US Market Access

InterSystems READY 2026 in Maryland (April 27-30) gives us direct access to US healthcare clients, hospital IT decision-makers, and investors. The US represents the largest market for clinical AI platforms, and InterSystems infrastructure powers healthcare data systems across major US hospital networks.

Presenting VIOSync at READY places us in front of the exact stakeholders who evaluate and deploy clinical decision support systems in US hospitals, creating visibility beyond the UK and European markets we’re currently focused on.

The Broader Context: Why Interoperability Determines Success

The history of clinical AI is littered with technically impressive systems that never deployed, not because the models didn’t work, but because the integration burden was too high.

Hospitals don’t have bandwidth to custom-integrate every AI tool. They need solutions that plug into existing infrastructure using standards they already support. FHIR represents that standard, but implementation is complex enough that it creates a competitive moat for companies that get it right.

Caelestinus exists because InterSystems, whose technology powers healthcare data infrastructure globally, recognized that healthtech startups often struggle with interoperability despite building solid products. The incubator provides structured access to the expertise and infrastructure that makes interoperable health technology actually possible.

For Aisthesis Medical, joining Caelestinus validates that we’re taking deployment seriously, not just building impressive models, but ensuring VIOSync can integrate into the hospital environments where it needs to run.

Looking Ahead: March – June 2026

The programme kicks off March 25th with a virtual event introducing all selected companies and outlining the incubation roadmap. Over the following three months, we’ll be working intensively on VIOSync FHIR integration, clinical validation planning, and preparing for the US demo day in April.

We’ll be sharing updates throughout the programme, particularly around InterSystems READY in Maryland where we’ll be presenting VIOSync to US healthcare stakeholders.

About Aisthesis Medical

Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven digital patient twin platform that goes beyond early sepsis prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.

Ready to Learn More?

If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.

📩 Get in touch: https://aisthesismed.com/contact/

🌐 Learn more about VIOSync: https://aisthesismed.com/product/